-
摘要: 高血压在全球和我国均是第一大慢性疾病,其心脑血管疾病并发症是我国居民首位死亡原因。近年来,国外研究多提示以社区为基础的高血压预防与诊疗模式是提高其控制率的有效途径。我国在20世纪开展的社区干预研究,以健康教育为主,虽取得了显著成果,但始终未能在全国范围内推广。进入21世纪后,我国在高血压预防与诊疗模式方面也进行了相关研究,但目前高血压管理仍存在诸多不足,故应积极探索适合我国国情的预防和诊疗模式,以提高高血压控制率。Abstract: Hypertension is the top chronic disease in both the world and China, and its complications of cardiovascular and cerebrovascular diseases are the leading cause of death in our country. Recently, plenty of foreign researches have suggested that the community-based mode of the prevention and treatment of hypertension is an effective way to improve the control rate. In the 20th century, China conducted research on community intervention, focusing on health education, which have achieved remarkable results but not been widely promoted. Since the beginning of the 21st century, China has also carried out many studies on the prevention and treatment of hypertension. However, there are still many shortcomings in the management of hypertension. Therefore, to improve the control rate of hypertension in China, we should actively explore the modes of prevention and treatment suitable for China's national condition.
-
Key words:
- hypertension /
- prevention /
- treatment /
- mode /
- prevalence rate
利益冲突 无 -
[1] Gao Y, Chen G, Tian H, et al. Prevalence of hypertension in china: a cross-sectional study[J]. PLoS One, 2013, 8:e65938. http://europepmc.org/articles/PMC3679057 [2] Wang J, Zhang L, Wang F, et al. Prevalence, awareness, treatment, and control of hypertension in China: results from a national survey[J]. Am J Hypertens, 2014, 27:1355-1361. doi: 10.1093/ajh/hpu053 [3] 李镒冲, 王丽敏, 姜勇, 等.2010年中国成年人高血压患病情况[J].中华预防医学杂志, 2012, 46:409-413. doi: 10.3760/cma.j.issn.0253-9624.2012.05.007 [4] Xu Y, Bi Y, Li M, et al.Prevalence, Awareness, Treatment, and Control of Hypertension in China: The China Metabolic Risk Factor Study[J]. Circulation, 2013, 127:A005. http://www.researchgate.net/publication/293476359_Prevalence_Awareness_Treatment_and_Control_of_Hypertension_in_China_The_China_Metabolic_Risk_Factor_Study [5] Li W, Gu H, Teo KK, et al.Hypertension prevalence, awareness, treatment, and control in 115 rural and urban communities involving 47 000 people from China[J]. J Hypertens, 2016, 34:39-46. doi: 10.1097/HJH.0000000000000745 [6] Li Z, Guo X, Zheng L, et al. Grim status of hypertension in rural China: results from Northeast China Rural Cardio-vascular Health Study 2013[J]. J Am Soc Hypertens, 2015, 9:358-364. doi: 10.1016/j.jash.2015.02.014 [7] Lu J, Lu Y, Wang X, et al.Prevalence, awareness, treatment, and control of hypertension in China: data from 1.7 million adults in a population-based screening study (China PEACE Million Persons Project)[J]. Lancet, 2017, 390:2549-2558. doi: 10.1016/S0140-6736(17)32478-9 [8] Su M, Zhang Q, Bai X, et al.Availability, cost, and prescription patterns of antihypertensive medications in primary health care in China: a nationwide cross-sectional survey[J]. Lancet, 2017, 390:2559-2568. doi: 10.1016/S0140-6736(17)32476-5 [9] Nissinen A, Tuomilehto J, Elo J, et al. Implementation of a hypertension control program in the county of North Karelia, Finland[J]. Public Health Rep, 1981, 96:503-513. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=PubMed000001227664 [10] Fortmann SP, Winkleby MA, Flora JA, et al. Effect of long-term community health education on blood pressure and hypertension control. The Stanford Five-City Project[J]. Am J Epidemiol, 1990, 132:629-646. doi: 10.1093/oxfordjournals.aje.a115705 [11] He J, Irazola V, Mills KT, et al.HCPIA Investigators. Effect of a Community Health Worker-Led Multicomponent Intervention on Blood Pressure Control in Low-Income Patients in Argentina: A Randomized Clinical Trial[J]. JAMA, 2017, 318:1016-1025. doi: 10.1001/jama.2017.11358 [12] Victor RG, Lynch K, Li N, et al.A Cluster-Randomized Trial of Blood-Pressure Reduction in Black Barbershops[J]. N Engl J Med, 2018, 378:1291-1301. doi: 10.1056/NEJMoa1717250 [13] Tian M, Ajay VS, Dunzhu D, et al. A Cluster-Randomized, Controlled Trial of a Simplified Multifaceted Management Program for Individuals at High Cardiovascular Risk (SimCard Trial) in Rural Tibet, China, and Haryana, India[J]. Circulation, 2015, 132:815-824. doi: 10.1161/CIRCULATIONAHA.115.015373 [14] 《中国高血压防治指南》修订委员会.中国高血压防治指南2018年修订版[J].心脑血管病防治, 2019, 19:1-45. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=xnxgbfz201901001
点击查看大图
计量
- 文章访问数: 546
- HTML全文浏览量: 36
- PDF下载量: 558
- 被引次数: 0